PHARMA TECHNOLOGY A/S Financials, key figures and credit report
Gross profit 48 337.0 kDKK FY 2025 +42.1% vs 2024
EBIT 15 764.1 kDKK FY 2025 +36.4% vs 2024
Net debt 3 455.8 kDKK FY 2025 -29.1% vs 2024
Quick ratio 1.6 FY 2025 +0 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 19 151.46 | 20 334.08 | 28 277.40 | 34 017.84 | 48 337.05 |
| Employee benefit expenses | -9 226.48 | -11 054.95 | -15 219.47 | -22 318.99 | -32 459.28 |
| Total depreciation | - 117.21 | - 140.47 | - 140.47 | - 140.47 | - 113.70 |
| EBIT | 9 807.77 | 9 138.66 | 12 917.47 | 11 558.39 | 15 764.06 |
| Other financial income | 4.41 | 55.73 | 31.79 | ||
| Other financial expenses | -36.58 | -35.10 | -11.99 | -15.23 | -15.21 |
| Pre-tax profit | 9 771.19 | 9 103.56 | 12 909.88 | 11 598.88 | 15 780.64 |
| Income taxes | -2 149.84 | -2 002.83 | -2 840.24 | -2 552.30 | -3 474.72 |
| Net earnings | 7 621.35 | 7 100.74 | 10 069.64 | 9 046.57 | 12 305.93 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 558.37 | 417.90 | 277.43 | 136.96 | 23.26 |
| Tangible assets total | 558.37 | 417.90 | 277.43 | 136.96 | 23.26 |
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 6 442.16 | 10 076.05 | 13 181.04 | 14 203.70 | 19 932.00 |
| Current amounts owed by group member comp. | 9 966.23 | 8 903.02 | 9 090.32 | 9 241.98 | 9 067.15 |
| Current other receivables | 59.11 | 186.07 | 65.81 | 56.17 | 56.96 |
| Current deferred tax assets | 12.61 | 26.94 | |||
| Short term receivables total | 16 467.50 | 19 165.15 | 22 337.17 | 23 514.46 | 29 083.04 |
| Cash and bank deposits | 1 691.23 | 1 379.33 | 1 381.03 | 2 578.47 | 4 994.23 |
| Cash and cash equivalents | 1 691.23 | 1 379.33 | 1 381.03 | 2 578.47 | 4 994.23 |
| Balance sheet total (assets) | 18 717.10 | 20 962.37 | 23 995.63 | 26 229.89 | 34 100.53 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Shares repurchased | 7 621.35 | 7 100.74 | 10 069.64 | 9 046.57 | 12 305.93 |
| Retained earnings | -7 621.35 | -7 100.74 | -10 069.64 | -9 046.57 | -12 305.93 |
| Profit of the financial year | 7 621.35 | 7 100.74 | 10 069.64 | 9 046.57 | 12 305.93 |
| Shareholders equity total | 8 121.35 | 7 600.74 | 10 569.64 | 9 546.57 | 12 805.93 |
| Provisions | 21.54 | 15.96 | 4.05 | ||
| Non-current deferred tax liabilities | 247.70 | ||||
| Non-current liabilities total | 247.70 | ||||
| Current trade creditors | 3 844.95 | 3 607.83 | 2 388.24 | 2 708.76 | 4 542.91 |
| Current owed to group member | 2 200.00 | 5 950.00 | 5 200.00 | 7 450.00 | 8 450.00 |
| Short-term deferred tax liabilities | 2 568.96 | 3 489.05 | |||
| Other non-interest bearing current liabilities | 4 281.56 | 3 787.85 | 5 833.70 | 3 955.60 | 4 812.65 |
| Current liabilities total | 10 326.51 | 13 345.68 | 13 421.94 | 16 683.31 | 21 294.60 |
| Balance sheet total (liabilities) | 18 717.10 | 20 962.37 | 23 995.63 | 26 229.89 | 34 100.53 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated